Weekly Analysts’ Ratings Changes for Atara Biotherapeutics (ATRA)

A number of research firms have changed their ratings and price targets for Atara Biotherapeutics (NASDAQ: ATRA):

• 12/29/2025 – Atara Biotherapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Atara Biotherapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – Atara Biotherapeutics was given a new $25.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 12/15/2025 – Atara Biotherapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Atara Biotherapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Atara Biotherapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Atara Biotherapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Atara Biotherapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/7/2025 – Atara Biotherapeutics was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.

Insider Activity at Atara Biotherapeutics

In other news, CEO Anhco Nguyen sold 2,915 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $13.19, for a total value of $38,448.85. Following the transaction, the chief executive officer owned 64,974 shares of the company’s stock, valued at approximately $857,007.06. This represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have sold 6,523 shares of company stock worth $86,038. 4.00% of the stock is owned by insiders.

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.